Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis

被引：2
作者：
Medina-De la Garza, Carlos Eduardo [1 ,2 ]
Flores-Torres, Armando Salvador [1 ]
Garcia-Hernandez, Marisela [1 ,3 ,4 ]
de los Angeles Castro-Corona, Maria [1 ,2 ]
机构：
[1] Univ Autonoma Nuevo Leon, Immunomodulat Unit, Ctr Res & Dev Hlth Sci CIDICS, Monterrey, Mexico
[2] Univ Autonoma Nuevo Leon, Serv Immunol, Av Gonzalitos 235,Mitras Ctr, Monterrey 64460, Mexico
[3] Univ Autonoma Nuevo Leon, Biochem & Mol Med Dept, Sch Med, Monterrey, Mexico
[4] Univ Autonoma Nuevo Leon, Univ Hosp Dr Jose E Gonzalez, Av Gonzalitos 235,Mitras Ctr, Monterrey 64460, Mexico
来源：
MEDICAL HYPOTHESES | 2022年 / 160卷
关键词：
Diethylcarbamazine; Drug repurposing; Pulmonary fibrosis; COVID-19-related pulmonary fibrosis; Post-COVID-19;
D O I：
10.1016/j.mehy.2022.110774
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Diethylcarbamazine, the antiparasitic drug, also possesses anti-inflammatory and immunomodulatory activities. The anti-fibrotic activity of diethylcarbamazine makes it a potential candidate to treat coronavirus disease 2019 (COVID-19)-related pulmonary fibrosis. Experimental and clinical studies should assess this possible effect.
引用
收藏
页数：2
相关论文
共 14 条
[1]   Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19? [J].
Abeygunasekera, Anuruddha ;
Jayasinghe, Saroj .
MEDICAL HYPOTHESES, 2020, 143
[2]   Antifibrotic effect of diethylcarbamazine combined with hesperidin against ethanol induced liver fibrosis in rats [J].
El-Sisi, Alaa El-Din El-Sayed ;
Sokar, Samia Salim ;
Shebl, Abdelhadi Mohamed ;
Mohamed, Dina Zakaria .
BIOMEDICINE & PHARMACOTHERAPY, 2017, 89 :1196-1206
[3]   Immunomodulatory effect of diethylcarbamazine in mice infected with Nocardia brasiliensis [J].
Garcia-Hernandez, M. ;
Castro-Corona, M. A. ;
Segoviano-Ramirez, J. C. ;
Brattig, N. W. ;
Medina-De la Garza, C. E. .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2014, 23 (01) :113-120
[4]   COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts [J].
John, Alison E. ;
Joseph, Chitra ;
Jenkins, Gisli ;
Tatler, Amanda L. .
IMMUNOLOGICAL REVIEWS, 2021, 302 (01) :228-240
[5]   Common pathway signature in lung and liver fibrosis [J].
Makarev, Eugene ;
Izumchenko, Evgeny ;
Aihara, Fumiaki ;
Wysocki, Piotr T. ;
Zhu, Qingsong ;
Buzdin, Anton ;
Sidransky, David ;
Zhavoronkov, Alex ;
Atala, Anthony .
CELL CYCLE, 2016, 15 (13) :1667-1673
[6]   Immunomodulatory activity of diethylcarbamazine on humoral, cellular cytokine response and respiratory burst in BALB/c mice [J].
Medina-De la Garza, Carlos E. ;
Guerrero-Ramirez, Graciela ;
Garcia-Hernandez, Marisela ;
Angeles Castro-Corona, M. ;
Torres-Lopez, Ernesto ;
Brattig, Norbert W. ;
Salinas-Carmona, Mario C. .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2012, 34 (03) :477-483
[7]   Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study [J].
Oh, Ki Kwang ;
Adnan, Md. ;
Ha Cho, Dong .
MEDICAL HYPOTHESES, 2021, 155
[8]   Anti-inflammatory effects of diethylcarbamazine: A review [J].
Peixoto, Christina Alves ;
Silva, Bruna Santos .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 734 :35-41
[9]   Diethylcarbamazine Attenuates the Development of Carrageenan-Induced Lung Injury in Mice [J].
Ribeiro, Edlene Lima ;
de Souza Barbosa, Karla Patricia ;
Fragoso, Ingrid Tavares ;
Matos Donato, Mariana Aragao ;
dos Santos Gomes, Fabiana Oliveira ;
da Silva, Bruna Santos ;
Silva, Amanda Karolina Soares e ;
Santos Rocha, Sura Wanessa ;
da Silva Junior, Valdemiro Amaro ;
Peixoto, Christina Alves .
MEDIATORS OF INFLAMMATION, 2014, 2014
[10]   Diethylcarbamazine attenuates the expression of pro-fibrogenic markers and hepatic stellate cells activation in carbon tetrachloride-induced liver fibrosis [J].
Rocha de Franca, Maria Eduarda ;
Santos Rocha, Sura Wanessa ;
Oliveira, Wilma Helena ;
Santos, Laise Aline ;
Vasconcelos de Oliveira, Anne Gabrielle ;
Sousa Barbosa, Karla Patricia ;
Santana Nunes, Ana Karolina ;
Rodrigues, Gabriel Barros ;
Los, Deniele Bezerra ;
Peixoto, Christina Alves .
INFLAMMOPHARMACOLOGY, 2018, 26 (02) :599-609
12